HONG KONG, GERMANTOWN, Md. and SUZHOU, China — Sirnaomics Ltd., a leading biopharmaceutical company engaging in discovery and development of advanced RNAi therapeutics, published a research article with NAR Cancer. The article reveals a novel mechanism of action of lead RNAi cancer drug candidate, STP707, a polypeptide nanoparticle (PNP) formulation...
Latest News
SEOUL, Korea – SK bioscience and the International Vaccine Institute (IVI) announced today that the typhoid conjugate vaccine developed by SK bioscience with technology transfer from IVI has achieved the World Health Organization prequalification (PQ), which paves the way for public procurement of the vaccine by UN organizations and gives a...
REHOVOT and RAMAT GAN , Israel — Skip Therapeutics developer of computational platform for design of Antisense Oligonucleotide (ASO) based therapies and Sheba Medical Center, one of the leading medical centers in the world, announced today that they have entered a collaboration for the development of ASO-based treatments for rare...
WALTHAM, Mass.— Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule RNA splicing modifiers, today announced that the Phase 1 multiple ascending dose (MAD) portion of its Phase 1 clinical study has now begun in Australia for the company’s SKY-0515 small molecule candidate targeting Huntington’s disease (HD). Huntington’s...
BOSTON, Mass. — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced positive results from the first interim analysis of the Part C patient cohort in its Phase 1 clinical trial of SKY-0515, an investigational treatment for Huntington’s disease (HD). At Day 84, patients receiving...
Experts have said they may develop a more effective kit for detecting sleeping sickness and medication against the condition in the next three years. Scientists at the Institute of Primate Research (IPR) in Nairobi and their counterparts from the European Union are currently working on what they say are more...
Barcelona, Spain – Researchers from the Infection Biology Lab at the Department of Medicine and Life Sciences (MELIS) at Pompeu Fabra University and the HIV Unit at Hospital del Mar Research Institute have shown that intradermal vaccination with the JYNNEOS vaccine against smallpox is the best option to protect people living with HIV from contracting...
For more than 3000 years, hundreds of millions of people have died or been left permanently scarred or blind by the relentless, incurable disease called smallpox. In 1967, Dr. D.A. Henderson became director of a worldwide campaign to eliminate this disease from the face of the Earth. SMALLPOX—THE DEATH OF...
A study of patients who were smokers at the time of early-stage non-small cell lung cancer (NSCLC) diagnosis revealed possible links to improved survival outcomes with smoking cessation in this population. The study results were reported in the journal Annals of Internal Medicine. This prospective, observational study was conducted at the...
SEOUL, South Korea — SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on Feb 27 that the FDA had granted an orphan drug designation for pancreatic cancer for SNB-101 (API: SN-38), a new polymer nanoparticle drug under development, based on the pre-clinical data of SNB-101 on pancreatic cancer animal model....